Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Gopinath Ranganna"'
1
Akademický článek
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
Autor: Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donnelly, Matthew A. Hummel, Roxann Shapiro, Melody Woods, Anita Rao, Vivek G Nayak, Gopinath Ranganna, Abhijit Barve
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Externí odkaz: https://doaj.org/article/c16131d828264fbc8bb2cf1ee253522f
Zobrazit plný text záznamu
2
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog
Autor: Thomas C, Blevins, Yaron, Raiter, Bin, Sun, Charles, Donnelly, Roxann, Shapiro, Anoop, Chullikana, Anita, Rao, Laxmikant, Vashishta, Gopinath, Ranganna, Abhijit, Barve
Publikováno v: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 36(6)
MYL-1601D is a proposed biosimilar of originator insulin aspart, NovologThis study assessed the immunogenicity, efficacy, and safety of MYL-1601D with Ref-InsAsp-US in patients with type 1 diabetes mellitus (T1D).This was a 24-week, open-label, rando
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bc717101a2617d3a8de30f3eabb24e8a
https://pubmed.ncbi.nlm.nih.gov/36114990
Zobrazit plný text záznamu
3
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study
Autor: Ulrike, Hövelmann, Yaron, Raiter, Anoop, Chullikana, Mark, Liu, Charles, Donnelly, Tracey, Lawrence, Nilanjan, Sengupta, Gopu, Cl, Gopinath, Ranganna, Abhijit, Barve
Publikováno v: Diabetes, obesitymetabolism. 23(12)
To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence (BE) of MYL-1601D biosimilar with originator, NovoLog (Ref-InsAsp-US), and NovoRapid (Ref-InsAsp-EU).This was a double-blind, randomized, crossover study that enrolled 71 he
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ccf59c2fe170fefc85f32dd839f9006b
https://pubmed.ncbi.nlm.nih.gov/34378861
Zobrazit plný text záznamu
5
741-P: Efficacy and Safety of MYL-1601D (Mylan's Insulin Aspart) Compared with Novolog (Novo Nordisk's Insulin Aspart) in Patients with Type 1 Diabetes (T1DM) after 24 Weeks
Autor: Gopinath Ranganna, Yaron Raiter, Roxann Shapiro, Bin Sun, Thomas Blevins, Charles Donnelly, Laxmikant Vashishta, Anoop Chullikana, Anita U. Rao, Abhijit Barve
Publikováno v: Diabetes. 70
MYL-1601D is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing Pichia pastoris yeast. This was a randomized, multicenter, open-label, parallel-group study to compare the safety and efficacy of MYL-1601D with NovoLog
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ea5213752dbd1354ce7e21296ffd2aa
https://doi.org/10.2337/db21-741-p
Zobrazit plný text záznamu
9
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
Autor: Cornelius F. Waller, Mark A. Socinski, Igor Bondarenko, Vivek G Nayak, Melody Woods, Matthew A. Hummel, Ashwini Vishweswaramurthy, Gopinath Ranganna, Roxann Shapiro, Katrin Beckmann, Subramanian Loganathan, Tazeen Idris, Anita Rao, Alexander Luft, Abhijit Barve, Charles Donnelly
Publikováno v: Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac16136f6d8b4302fe641a6d6d0d28fd
https://doi.org/10.1177/17588359211045845
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje